Tech Company Financing Transactions

Curevo Vaccine Funding Round

Medicxi Ventures, Adjuvant Capital and GC Pharma invested in a $110 million Series B capital raise for Curevo Vaccine. The round was announced on 3/17/2025.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

21540 - 30th Dr. Southeast 260
Bothell, WA 98021
USA

Phone

(206) 492-5722

Website

www.curevovaccine.com

Email Address

[email protected]

Overview

Curevo Vaccine is a clinical-stage biotechnology company, focused on bringing new generation adjuvanted subunit vaccines to market. We combine excellence in protein and adjuvant biology to create vaccines of global importance.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

George Simeon

        

Chief Financial Officer

Gregory Curhan

        

VP - General Counsel

Julie Brooks

        

VP - Operations

Lisa Shelton

        

VP - Operations

Andrea Wang

        

Browse more venture capital transactions:

Prev: 3/15/2025: Mutuus venture capital transaction
Next: 3/17/2025: Latigo Biotherapeutics venture capital transaction

Share this article

About Database of VC Transactions

We do our best to document tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary